Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II of Erlotinib an Epidermal Growth Factor Receptor Inhibitor in the Treatment of Myelodysplastic Syndrome

NCT00570375 is registered in ClinicalTrials.gov with University of Cincinnati as lead sponsor.

NCT NCT00570375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00570375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II of Erlotinib an Epidermal Growth Factor Receptor Inhibitor in the Treatment of Myelodysplastic Syndrome
Lead sponsor
University of Cincinnati
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2007
Completion date
April 30, 2009
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome